September 01, 2026

10 Growing US Metro Areas to Consider for Private Practice

These 10 metropolitan areas recorded population growth and had recently completed, ongoing, or announced health care infrastructure projects.

MDSpire News

August 25, 2026

Outreach screening may uncover hearing loss

Recommended treatment was implemented in only about one-third of traceable cases, leaving substantial hearing care gaps after detection.

MDSpire News

August 19, 2026

Full vs limited FESS tested in CRSwNP

Investigators compare full and limited surgery across patient-reported and clinical outcomes over 24 months.

MDSpire News

August 04, 2026

QOL After Head and Neck Reconstruction

A prospective cohort study suggests that clinically meaningful quality‐of‐life changes continue well beyond the first postoperative year, with one‐year complications emerging as the strongest potentially modifiable predictor of later decline.

MDSpire News

July 16, 2026

Model Favors Septoplasty at 24 Months

A UK trial-based economic evaluation found uncertain cost-effectiveness at 12 months, but a model extrapolating outcomes to 24 months estimated a lower cost per quality-adjusted life year for immediate surgery.

MDSpire News

July 13, 2026

Side Effects: Signals in Strange Places

From breathier speech to breastfeeding history, metamaterial eye coils, and antifibrotic GLP-1 effects in mice, this week’s studies remind us that the most interesting signal is often hiding somewhere clinicians were not looking.

MDSpire News

June 22, 2026

Deprivation Tied to Lower HNC-Specific QOL

The differences were present before patients began any treatment, suggesting quality-of-life gaps may be established before therapy begins.

MDSpire News

June 19, 2026

Most Miss Streamlined Neck Mass Dx Path

Same-visit biopsy and fewer empiric workup steps were linked to faster pathologic diagnosis in a retrospective analysis.

MDSpire News

June 15, 2026

FDA Approves Low-Dose Macrocyclic Contrast Agent for MRI

The macrocyclic gadolinium-based contrast agent has a recommended dose of 0.01 mmol/kg actual body weight.

MDSpire News

June 05, 2026

Chemoimmunotherapy Linked to HNSCC Response

Higher pathologic response rates with chemoimmunotherapy versus immunotherapy alone call for phase 3 trials, but survival implications remain unknown.

MDSpire News